TG Therapeutics, Inc. (NKB2.F)
- Previous Close
12.77 - Open
12.98 - Bid 12.90 x 150000
- Ask 13.15 x 150000
- Day's Range
12.98 - 12.98 - 52 Week Range
6.24 - 32.71 - Volume
80 - Avg. Volume
537 - Market Cap (intraday)
2.041B - Beta (5Y Monthly) 2.32
- PE Ratio (TTM)
162.25 - EPS (TTM)
0.08 - Earnings Date Apr 29, 2024 - May 3, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
59.88
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
www.tgtherapeutics.comRecent News: NKB2.F
Performance Overview: NKB2.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKB2.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKB2.F
Valuation Measures
Market Cap
2.01B
Enterprise Value
1.91B
Trailing P/E
151.78
Forward P/E
136.99
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
8.68
Price/Book (mrq)
13.14
Enterprise Value/Revenue
8.17
Enterprise Value/EBITDA
73.10
Financial Highlights
Profitability and Income Statement
Profit Margin
5.42%
Return on Assets (ttm)
4.93%
Return on Equity (ttm)
11.57%
Revenue (ttm)
233.66M
Net Income Avi to Common (ttm)
12.67M
Diluted EPS (ttm)
0.08
Balance Sheet and Cash Flow
Total Cash (mrq)
217.51M
Total Debt/Equity (mrq)
69.25%
Levered Free Cash Flow (ttm)
-47.55M
Research Analysis: NKB2.F
Company Insights: NKB2.F
NKB2.F does not have Company Insights